Ollin BiosciencesBiotech
Ollin Biosciences develops cell therapy manufacturing platforms to scale production of regenerative medicines.
$330MSeries B
Investor undisclosed
A $330M Series B for cell therapy manufacturing signals that the bottleneck has shifted from drug discovery to production—investors are betting the clinical wins are real enough that scale is now the constraint. At this stage and size, Ollin is likely building out GMP facilities and automation to hit cost/throughput targets that make these therapies economically viable. If you're in adjacent biotech infrastructure (diagnostics, logistics, quality control), this validates that there's serious capital flowing to solve the "how do we make this at scale" problem, not just the "does it work" problem.